Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT4FDG6)

• DTT Name: Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DTT Info
• Gene Name: CACNA1B

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hesperidin	DMI5DW1	Vascular purpura	3B60	Approved	[1]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[2]
Ziconotide	DMSLJP4	Pain	MG30-MG3Z	Approved	[3]

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[4]
Ralfinamide	DMUNMY0	Neuropathic pain	8E43.0	Phase 3	[5]
CNV-2197944	DMLT7JV	Pain	MG30-MG3Z	Phase 2	[6]

5 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ritanserin	DM0X36Y	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[7]
PD-0204318	DMGKVPH	Pain	MG30-MG3Z	Terminated	[9]
PD-157667	DM61NFD	N. A.	N. A.	Terminated	[10]
PD-29361	DMQRHMT	N. A.	N. A.	Terminated	[11]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[12]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CNSB-004	DMHAI0M	Pain	MG30-MG3Z	Preclinical	[8]

11 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conotoxin	DMQG2MC	Discovery agent	N.A.	Investigative	[13]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[14]
GNF-PF-3464	DMWAKHD	Discovery agent	N.A.	Investigative	[1]
KYS-05090	DM92RHP	Discovery agent	N.A.	Investigative	[15]
NSC-180246	DMXBRCI	Discovery agent	N.A.	Investigative	[1]
NSC-87509	DMSYT0A	Discovery agent	N.A.	Investigative	[1]
omega-conotoxin GVIA	DM4BQFW	Discovery agent	N.A.	Investigative	[16]
PD-151307	DMHD8UL	Discovery agent	N.A.	Investigative	[17]
PD-167341	DM9LJEP	Discovery agent	N.A.	Investigative	[17]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[10]
TROX-1	DMIF6NS	Discovery agent	N.A.	Investigative	[18]

References

• [1] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [2] Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
• [3] Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
• [4] N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
• [5] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [6] Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
• [7] N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
• [8] CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
• [9] US patent application no. 2012,0172,429, Permanently charged sodium and calcium channel blockers as anti- inflammatory agents.
• [10] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [11] Synthesis and structure-activity relationship of substituted 1,2,3,4-tetrahydroisoquinolines as N-type calcium channel blockers. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2415-8.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [13] Treatment with conotoxin, an 'N-type' calcium channel blocker, in neuronal hypoxic-ischemic injury. Brain Res. 1990 Dec 24;537(1-2):256-62.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 533).
• [15] Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
• [16] Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem. 2000 Nov 10;275(45):35335-44.
• [17] Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic proper... J Med Chem. 1999 Oct 7;42(20):4239-49.
• [18] Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther. 2010 Aug;334(2):545-55.